One-Year Outcome of PreserFlo MicroShunt Implantation in Patients with Open Angle Glaucoma: Real-World Data from a Tertiary Centre.

Purpose: To evaluate the one-year clinical outcomes, safety profile, and surgical success of the PreserFlo Methods: This retrospective study included 40 eyes of 31 patients undergoing PreserFlo MicroShunt implantation performed by two experienced surgeons using a standard ab-externo technique with mitomycin C (0.04% for 3 minutes) and a structured postoperative corticosteroid tapering regimen. Outcomes assessed at 12 months included intraocular pressure (IOP), number of topical glaucoma medications, visual acuity, optic nerve and retinal nerve fibre layer parameters, visual field indices, complications, and surgical success. Complete success was defined as achieving target IOP without medications, while qualified success allowed adjunctive medications. Results: Mean IOP was reduced from a preoperative median of 19.0 mmHg to 11.5 mmHg at 12 months ( Conclusion: PreserFlo MicroShunt implantation was associated with reductions in IOP and glaucoma medication burden at one year, with generally acceptable short-term safety outcomes. These findings support its role as an effective bleb-forming minimally invasive glaucoma surgery option for patients requiring lower target IOPs, including those with advanced glaucoma. However, the results should be interpreted in the context of the modest sample size, retrospective design, absence of a comparator group, and need for postoperative interventions. This study provides the first Malaysian real-world data on PreserFlo MicroShunt outcomes and adds to the growing regional evidence base for its use.